Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 02 10 2020
revised: 08 03 2021
accepted: 17 03 2021
pubmed: 30 3 2021
medline: 3 11 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

To analyse the strains collected during a 1-year survey of ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae, in order to investigate the molecular mechanisms potentially responsible for their resistant phenotype. Clinical KPC-producing K. pneumoniae isolates were collected from 31 patients in six different hospitals in Rome. For eight of the patients, an additional strain grown before the start of treatment was also available, bringing the total of isolates studied to 39. Antimicrobial susceptibility was determined by automated system, broth microdiluition and E-test as appropriate. In silico analysis of acquired resistance genes was achieved by whole-genome sequencing, while multilocus sequence typing and core genome multilocus sequence typing were employed for molecular typing. Mutations associated with ceftazidime-avibactam resistance were identified by Sanger sequencing of the bla Molecular analyses highlighted the circulation of the ST512, 101 and 307 high-risk clones; 26 of the 31 patients carried a mutated KPC variant, five had a wild-type KPC-3. Among the KPC variants detected, 11 were different mutations within the bla Different mutations including single amino-acid substitutions, insertions or deletions within the bla

Identifiants

pubmed: 33775814
pii: S1198-743X(21)00135-X
doi: 10.1016/j.cmi.2021.03.001
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azabicyclo Compounds 0
Bacterial Proteins 0
Drug Combinations 0
Porins 0
avibactam, ceftazidime drug combination 0
Ceftazidime 9M416Z9QNR
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1040.e1-1040.e6

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Carolina Venditti (C)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Ornella Butera (O)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Marcello Meledandri (M)

San Filippo Neri Hospital, Rome, Italy.

Maria Pia Balice (MP)

Santa Lucia Hospital, Rome, Italy.

Giulio Cesare Cocciolillo (GC)

S. Eugenio Hospital, Rome, Italy.

Carla Fontana (C)

TorVergata University, Rome, Italy.

Silvia D'Arezzo (S)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Chiara De Giuli (C)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Mario Antonini (M)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Alessandro Capone (A)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Francesco Messina (F)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Carla Nisii (C)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy. Electronic address: carla.nisii@inmi.it.

Antonino Di Caro (A)

National Institute for Infectious Diseases (INMI) L. Spallanzani, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH